The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FDG-PET/CT (PET) in the early prediction of benefit from first-line chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer (mCRC).
Lisa Salvatore
No relevant relationships to disclose
Fotios Loupakis
No relevant relationships to disclose
Chiara Cremolini
No relevant relationships to disclose
Marta Schirripa
No relevant relationships to disclose
Carlotta Antoniotti
No relevant relationships to disclose
Federica Marmorino
No relevant relationships to disclose
Federica Zoratto
No relevant relationships to disclose
Francesca Bergamo
No relevant relationships to disclose
Isa Maura Brunetti
No relevant relationships to disclose
Elisabetta Pfanner
No relevant relationships to disclose
Gianluca Masi
No relevant relationships to disclose
Dario Genovesi
No relevant relationships to disclose
Elena Filidei
No relevant relationships to disclose
Assuero Giorgetti
No relevant relationships to disclose
Alfredo Falcone
No relevant relationships to disclose